NKTR · Nektar Therapeutics
United States · RS rating 17 · As of 2026-11-03
| Price | 37.76 USD |
|---|---|
| 1-day change | +2.2% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 34 / 9 / 25 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 19 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +4.8% |
| Sales growth Q/Q | +85.0% |
| Distance from 52-week high | +62.4% |
| Market cap (USD) | $3.0B |